Hugh Rosen

Biography

 Hugh Rosen, M.D., Ph.D., joins ActivX as President and Chairman with a 30+ year career in the pharmaceutical, biotechnology and academic sectors. Hugh’s career has been one of significant achievements. Following training in medicine in Cape Town, he received his D.Phil. as a Royal Commission for the Exhibition of 1851 Scholar at the University of Oxford. He then spent 11 years at Merck Research Laboratories before becoming a Professor at The Scripps Research Institute (TSRI) in 2002. At TSRI, his research focus has been on chemical and biological approaches to the molecular mechanisms regulating lymphocyte trafficking. As part of this research, he co-invented ozanimod with the Edward Roberts lab and was a scientific founder of Receptos, which was acquired by Celgene in 2015 for $7.3 Billion. Hugh is also a scientific founder of BlackThorn Therapeutics which recently closed a $40M Series A. He serves as an independent Board member at Regulus Therapeutics and will also remain on the faculty of TSRI

Research Interest

 chemical and biological approaches to the molecular mechanisms regulating lymphocyte trafficking